CDNA CareDx, Inc. Insider Trading

CEO John Walter Jr Hanna sells 21,998 shares of CDNA at $24.02 under 10b5-1 plan adopted 2024-12-13

John Walter Jr Hanna, President and CEO, sold 21,998 shares of CareDx, Inc. at $24.02 per share on 2026-06-11 under a pre-arranged 10b5-1 trading plan adopted on 2024-12-13. This was a scheduled, non-discretionary transaction. Post-transaction holdings remain substantial at 649,642 shares. The stock trades near its 52-week high of $24.13 and has appreciated 20.6% over 30 days and 36.8% over 90 days, reflecting recent momentum. The company generated $117.7M in latest quarterly revenue with 13.8% annual revenue growth, though it remains unprofitable on a full-year basis. The scheduled nature of this transaction precludes attribution to discretionary strategic reasoning.

Director Peter Maag sold 35,552 shares of CDNA for $1.2M across 3 transactions on 2024-08-20

Director Peter Maag executed 3 separate sales totaling 35,552 shares for $1,174,492.68 on 2024-08-20, reducing his holdings by 9.7% from 365,576 shares to 330,024 shares. The transactions occurred at prices ranging from $32.67 to $33.25, with a blended average of $33.04—above the current price of $30.96 but 8.9% below the 52-week high of $33.99. Notably, this sale occurs in the context of a company that reported negative net income ($-1.4M in the latest quarter), declining annual revenue growth of -12.9%, and unprofitability over the most recent full fiscal year. The 30-day and 90-day price appreciation (+63.0% and +94.2% respectively) establishes a materially elevated valuation backdrop for the transaction, contrasting sharply with the company's negative earnings trajectory.

Johnson Alexander L sells 61,023 shares at avg $32.96; holds 285.0K shares post-sale; stock -8.9% from 52-week high amid -12.9% annual revenue decline.

Johnson Alexander L executed 2 separate sales totaling 61,023 shares for $2,011,414.28 on 2024-08-20 and 2024-08-21, reducing holdings by 17.6% to 285.0K shares. The sales occurred at $33.17 and $32.58, prices near the 52-week high of $33.99 and well above the current price of $30.96. CareDx fundamentals show weakness: annual revenue declined 12.9% year-over-year to $92,274,000.00, and the company posted a net loss of $1,394,000.00 in its latest quarter while unprofitable over the full fiscal year. The timing of large equity reductions during a period of deteriorating financials and stock proximity to 52-week highs merits investor attention, though his cross-ticker track record shows no pattern of well-timed sales historically.

CFO Alexander L Johnson sells 34,231 shares at $33.55 avg, reducing stake by 10.7% as stock rallies 76.8% in 30 days.

Johnson Alexander L executed 3 separate sales totaling 34,231 shares for $1,148,334.85, reducing his holdings from 319,214 to 284,983 shares (a -10.7% decrease). The sales occurred at prices ranging from $33.52 to $33.83, near the stock's 52-week high of $33.99, after the company's shares have climbed 76.8% over 30 days and 110.7% over 90 days. Against this backdrop of strong recent price momentum, the insider's decision to liquidate over one-tenth of his position merits investor attention. CareDx remains unprofitable with net income of $-1,394,000.00 in the latest quarter and annual revenue growth of -12.9%, suggesting the recent rally is not driven by fundamental improvement.